title: [SIRT1 Influences the Sensitivity of A549 Non-small Cell Lung Cancer Cell Line to  Cisplatin via Modulating the Noxa Expression].
abstract: BACKGROUND
  The resistance of non-small cell lung cancer cells to cisplant is a common clinical phenomenon which could induce a poor therapeutic effect and should be difficult problem to be solved. SIRT1 and Noxa expression are associated with the chemotherapy for tumors. The present study focused on how SIRT1 expression influence the senstivity of non-small cell lung cancer cells and dissected the potential mechanism involved with Noxa.
  
  
  METHODS
  The difference of SIRT1 and Noxa expression between A549 cells and A549/DDP cells was detected by real-time quantitative PCR (qRT-PCR) and Western blot. SIRT1 targeted siRNA was uesed to inhibit the SIRT1 expression in A549/DDP, after transfection, Cell Titer Blue assay, flow cytometry were performed to analyze the cell viability, cell cycle and cell apoptosis in order to reveal the effect of inhibition of SIRT1 on sensitivity of A549/DDP cells to cisplant. Moreover, the expression changes of Noxa in A549/DDP cells after siRNA treatment were detected by qRT-PCR and Western blot.
  
  
  RESULTS
  There was a significant difference in senstivity to cisplant between A549 and A549/DDP cells. Compared with A549 cells, the A549/DDP cells showed a higher SIRT1 expression and lower Noxa expression. After transfected with SIRT1 targeted siRNA, the cell viability decreased accompanied with a increasing apoptosis rate, meanwhile, higher percent of G2/M phase was detected after the 4 μg/mL cisplant treatment. Further more, inhibition of SIRT1 could induce the Noxa expression in A549/DDP cells.
  
  
  CONCLUSIONS
  Higher SIRT1 expression may induce resistance to cisplant in A549 cells. SIRT1 inhibition may improve the sensitivity of A549/DDP cells to cisplantin though modulating the Noxa expression. .
authors.affiliation: Department of Thoracic-Cardio Surgery, the Affiliated Drum Tower Hospital of Nangjing University Medical School, Nanjing 210008, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Cao
authors.affiliation: Department of Thoracic-Cardio Surgery, the Affiliated Drum Tower Hospital of Nangjing University Medical School, Nanjing 210008, China.
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: He
authors.affiliation: Department of Thoracic-Cardio Surgery, the Affiliated Drum Tower Hospital of Nangjing University Medical School, Nanjing 210008, China.
authors.forename: Wengong
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Thoracic-Cardio Surgery, the Affiliated Drum Tower Hospital of Nangjing University Medical School, Nanjing 210008, China.
authors.forename: Minke
authors.initials: M
authors.lastname: Shi
mesh_terms: D000072283:A549 Cells; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D002453:Cell Cycle / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics* / Q000378:metabolism; D056564:Sirtuin 1 / Q000235:genetics* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C498702:PMAIP1 protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; C447939:SIRT1 protein, human; D056564:Sirtuin 1; D002945:Cisplatin